Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies are urgently needed. This Phase I multipart expansion study assessed oral c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:NPJ Breast Cancer
Autors principals: Smyth, Lillian M., Batist, Gerald, Meric-Bernstam, Funda, Kabos, Peter, Spanggaard, Iben, Lluch, Ana, Jhaveri, Komal, Varga, Andrea, Wong, Andrea, Schram, Alison M., Ambrose, Helen, Carr, T. Hedley, de Bruin, Elza C., Salinas-Souza, Carolina, Foxley, Andrew, Hauser, Joana, Lindemann, Justin P. O., Maudsley, Rhiannon, McEwen, Robert, Moschetta, Michele, Nikolaou, Myria, Schiavon, Gaia, Razavi, Pedram, Banerji, Udai, Baselga, José, Hyman, David M., Chandarlapaty, Sarat
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8052445/
https://ncbi.nlm.nih.gov/pubmed/33863913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-021-00251-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars